Cytrx Corp (CYTR)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

11726 SAN VICENTE BOULEVARD LOS ANGELES, CA 90049

Develops products, primarily in the areas of ribonucleic acid interference (RNAi) and small molecule therapeutics, for the human health-care market. RNAi is a new technology for silencing genes in living cells and organisms.

Data as of 2020-08-09
Market Cap22.495 Million Shares Outstanding33.638 Million Avg 30-day Volume47.929 Thousand
P/E Ratio Dividend Yield EPS-0.2
Price/Sales Price cash flow ratio Price free cash flow ratio-5.5
Book Value0.42 Price to Tangible Book1.59 Alpha0.05
Short Interest Ratio1.96 % Short Interest to Float0.9 R-squared0.02709
BETA2.79647 52-week High/Low0.847 / 0.21 Stddev0.714465
View SEC Filings from CYTR instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 0 0 (0.0%)
13F Filers holding this stock: 3 0 (0.0%)
Aggregate 13F shares on 03/31/2020: 14.721 Thousand 0
Aggregate 13F shares on 12/31/2019: 11.387 Thousand 0
Percent change: 29.28%
Funds creating new positions: 1
Funds Adding to an existing position:
Funds closing out their position:
Funds reducing their position:
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding CYTR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CYTR BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

COHEN CHERYL

  • Director
0 2020-07-02 0

SHAH JAISIM

  • Director
0 2020-06-15 0

CURTIS ERIC SVP & COO

  • Officer
0 2020-03-09 0

CALOZ JOHN Y CHIEF FINANCIAL OFFICER

  • Officer
0 2019-12-13 1

KRIEGSMAN STEVEN A CEO

  • Officer
  • Director
  • CHAIRMAN OF THE BOARD
0 2019-12-13 1

IGNARRO LOUIS

  • Director
0 2019-12-13 1

BRIEN EARL W

  • Director
0 2019-12-13 1

CALDWELL JOEL K

  • Director
0 2019-12-13 1

LEVITT DANIEL J

  • Director
0 2018-05-14 0

KRATZ FELIX VICE PRESIDENT DRUG DISCOVERY

  • Officer
0 2017-12-15 0

CHAWLA SHANTA M.D. SENIOR VP-DRUG DEVELOPMENT

  • Officer
2,100 2017-06-13 0

RUBINFELD JOSEPH

  • Director
0 2016-12-15 0

WIELAND DOUGLAS SCOTT SR VP - DRUG DEVELOPMENT

  • Officer
0 2016-12-15 0

CHAWLA ANITA J

  • Director
0 2016-12-15 0

WARE OLIVIA C CHIEF COMMERCIAL OFFICER

  • Officer
0 2016-01-11 0

LEVIN BEN SVP-LEGAL AFFAIRS/GC/SECY

  • Officer
0 2015-12-15 0

SELTER ERIC JAY

  • Director
0 2015-12-15 0

WENNEKAMP RICHARD L.

  • Director
0 2014-12-15 0

LINK MAX

  • Director
77,069 2014-08-12 0

SELTER MARVIN R

  • Director
0 2013-12-10 0

PATTERSON SCOTT BRADFORD

  • 10% Owner
4,577,605 2013-12-10 0

GEYER DAVID SCOTT SR. V.P. OF MANUFACTURING

  • Officer
0 2011-12-12 0

FOGELMAN MITCHELL K CHIEF FINANCIAL OFFICER

  • Officer
  • Director
No longer subject to file 2010-10-15 0

BARBER JACK R CHIEF SCIENTIFIC OFFICER

  • Officer
0 2009-07-01 0

NG SHI CHUNG SR VP RESEARCH & DEVELOPMENT

  • Officer
0 2008-11-21 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments